Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.45 |
| ▸ | CCR5 | P51681 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.39 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.38 |
| ▸ | FAAH | O00519 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3915410 | 1.00 | OPRM1 (0.57) | OPRM1OPRD1CCR5CYP3A4USP2 | |
| SCHEMBL23686901 | 0.77 | CYP19A1 (0.45) | CYP3A4USP2MAPTPPARA | |
| SCHEMBL3902678 | 0.76 | OPRM1 (0.52) | OPRM1OPRD1CYP3A4USP2MAPT | |
| SCHEMBL3900977 | 0.75 | OPRM1 (0.45) | OPRM1CCR5TRPV1FAAH | |
| SCHEMBL3908788 | 0.75 | OPRM1 (0.45) | OPRM1CCR5TRPV1FAAH | |
| SCHEMBL3900975 | 0.75 | OPRM1 (0.45) | OPRM1CCR5TRPV1FAAH | |
| SCHEMBL3908785 | 0.75 | OPRM1 (0.45) | OPRM1CCR5TRPV1FAAH | |
| SCHEMBL3897938 | 0.75 | OPRM1 (0.45) | OPRM1CCR5TRPV1FAAH | |
| SCHEMBL3897943 | 0.75 | OPRM1 (0.45) | OPRM1CCR5TRPV1FAAH | |
| SCHEMBL3900984 | 0.73 | OPRM1 (0.46) | OPRM1OPRD1CCR5TRPV1FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-7622598-B2 | Phenol derivatives and antitrypanosoma preventive/therapeutic agent comprising the same as active ingredient | ARIGEN PHARMACEUTICALS, INC. (JP) | 2009-11-24 | — | — | US | disclosed |
| EP-1681280-B1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ARIGEN PHARMACEUTICALS INC (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-1681280-B1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | ARIGEN PHARMACEUTICALS INC (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | ARIGEN, INC. (JP) | 2007-09-06 | — | — | US | disclosed |
| EP-1681280-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT CONTAINING THE SAME AS ACTIVE INGREDIENT | aRigen, Inc. (JP) | 2006-07-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208078-A1 | NOVEL PHENOL DERIVATIVES AND ANTITRYPANOSOMA PREVENTIVE/THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | TYR, H1-3, H1-0 | OPRM1 2281/4885OPRD1 1074/4885CCR5 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.